A breakthrough therapy for cystic fibrosis appears to create an unexpected metabolic trade-off that could reshape treatment strategies for this genetic disorder. While dramatically improving lung function and survival, the triple-drug combination ETI is fundamentally altering how patients process nutrients and store energy.
A comprehensive analysis of 126 studies reveals that 90% of adults with cystic fibrosis experience weight increases after starting ETI therapy, with statistically significant gains documented in 61% of cases. The metabolic shifts extend beyond simple weight gain—patients develop measurable increases in both fat mass and lean muscle tissue, alongside concerning elevations in blood lipid profiles. Total cholesterol rose significantly in 72% of studies examined, while LDL cholesterol increased in 80% of investigations.
This metabolic transformation represents a dramatic reversal for a patient population historically characterized by malnutrition and difficulty maintaining healthy weight. The findings suggest ETI's correction of the underlying chloride channel defect may restore normal nutrient absorption so effectively that patients now face obesity and cardiovascular risk factors previously rare in this population. However, the research landscape remains fragmented, with many findings emerging from conference presentations rather than peer-reviewed publications. The long-term cardiovascular implications remain unclear, as do optimal management strategies for preventing metabolic complications while preserving ETI's life-extending benefits. This emerging pattern demands urgent development of nutritional guidelines and metabolic monitoring protocols specifically tailored for the post-ETI era of cystic fibrosis care.